Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M.

Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.

PMID:
24658074
2.

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A.

Clin Cancer Res. 2012 Feb 15;18(4):1177-85. doi: 10.1158/1078-0432.CCR-11-0564. Epub 2012 Jan 6.

3.

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Int J Cancer. 2014 Nov 1;135(9):2215-22. doi: 10.1002/ijc.28863. Epub 2014 Apr 17.

4.

KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.

Lewandowska MA, Jóźwicki W, Żurawski B.

Mol Diagn Ther. 2013 Jun;17(3):193-203. doi: 10.1007/s40291-013-0025-8.

5.

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.

Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.

6.

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.

Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, François E, Saint-Paul MC, Pedeutour F.

Ann Surg Oncol. 2010 May;17(5):1429-34. doi: 10.1245/s10434-009-0864-z. Epub 2010 Jan 5.

PMID:
20049644
7.

Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.

Buxhofer-Ausch V, Ausch C, Zeillinger R, Oberkanins C, Dandachi N, Reiner-Concin A, Kriegshäuser G.

Dis Markers. 2013;34(3):171-7. doi: 10.3233/DMA-120960.

8.

Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.

Dono M, Massucco C, Chiara S, Sonaglio C, Mora M, Truini A, Cerruti G, Zoppoli G, Ballestrero A, Truini M, Ferrarini M, Zupo S.

Mol Med. 2013 Feb 8;18:1519-26. doi: 10.2119/molmed.2012.00175.

9.

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.

Spindler KG, Appelt AL, Pallisgaard N, Andersen RF, Jakobsen A.

Br J Cancer. 2013 Dec 10;109(12):3067-72. doi: 10.1038/bjc.2013.633. Epub 2013 Nov 21.

10.

Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.

Rako I, Jakic-Razumovic J, Katalinic D, Sertic J, Plestina S.

Neoplasma. 2012;59(4):376-83. doi: 10.4149/neo_2012_049.

PMID:
22489692
11.

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.

Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, van der Spoel P, Ramírez-Moreno R, Verhoef C, Ijzermans JN, Wang Y, Gratama JW, Foekens JA, Sleijfer S, Martens JW.

Int J Cancer. 2013 Jul;133(1):130-41. doi: 10.1002/ijc.27987. Epub 2013 Feb 9.

12.

Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Ličar A, Cerkovnik P, Novaković S.

Med Oncol. 2011 Dec;28(4):1048-53. doi: 10.1007/s12032-010-9631-z. Epub 2010 Jul 20.

PMID:
20645028
13.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P.

Ann Oncol. 2011 Jul;22(7):1535-46. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.

14.

Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.

Mohamed Suhaimi NA, Foong YM, Lee DY, Phyo WM, Cima I, Lee EX, Goh WL, Lim WY, Chia KS, Kong SL, Gong M, Lim B, Hillmer AM, Koh PK, Ying JY, Tan MH.

Mol Oncol. 2015 Apr;9(4):850-60. doi: 10.1016/j.molonc.2014.12.011. Epub 2015 Jan 7.

15.

Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.

Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.

PMID:
19474002
16.

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.

BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.

17.

Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.

Bennani B, Gilles S, Fina F, Nanni I, Ibrahimi SA, Riffi AA, Nejjari C, Benajeh DA, El Abkari M, Martin PM, Ouafik L.

Int J Biol Markers. 2010 Oct-Dec;25(4):179-84.

PMID:
21161938
18.

A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer.

Galbiati S, Damin F, Pinzani P, Mancini I, Vinci S, Chiari M, Orlando C, Cremonesi L, Ferrari M.

PLoS One. 2013;8(3):e59939. doi: 10.1371/journal.pone.0059939. Epub 2013 Mar 25.

19.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
20.

KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.

Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC.

J Mol Diagn. 2012 May-Jun;14(3):247-55. doi: 10.1016/j.jmoldx.2012.01.011. Epub 2012 Mar 14.

PMID:
22425762
Items per page

Supplemental Content

Write to the Help Desk